



REGULATED INFORMATION
JULY 27, 2012

TiGenix receives transparency notification

Leuven (Belgium) – July 27, 2012 – TiGenix NV (NYSE Euronext Brussels: TIG) announced today that it has received a notification pursuant to the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by ING Groep N.V. and ING Belgium S.A. regarding the crossing below the lowest threshold of 3% by ING Belgium S.A. (which previously held 4.91% of the TiGenix shares) on 17 July 2012, to continue to hold 2.99% of the shares.

The chain of controlled undertakings through which the holdings are effectively held, is as follows: ING Group N.V. controls ING Bank N.V., that controls ING Belgium S.A. ING Group N.V. is a parent undertaking.

For further details regarding this notification, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>, where the notification has been published.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect[®], and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.